Cellumed Co. Ltd (KQ:049180) — Market Cap & Net Worth
Market Cap & Net Worth: Cellumed Co. Ltd (049180)
Cellumed Co. Ltd (KQ:049180) has a market capitalization of $37.57 Million (₩55.44 Billion) as of August 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22905 globally and #1473 in its home market, demonstrating a -12.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cellumed Co. Ltd's stock price ₩1009.00 by its total outstanding shares 54948055 (54.95 Million). See 049180 capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Cellumed Co. Ltd Market Cap History: 2015 to 2026
Cellumed Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $294.92 Million to $37.57 Million (-18.24% CAGR).
Index Memberships
Cellumed Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$202.56 Billion | 0.02% | #715 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$202.56 Billion | 0.02% | #715 of 1384 |
Weight: Cellumed Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cellumed Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cellumed Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Cellumed Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $294.92 Million | $17.73 Billion | -$11.35 Billion | 0.02x | N/A |
| 2016 | $560.42 Million | $9.81 Billion | -$36.85 Billion | 0.06x | N/A |
| 2017 | $364.56 Million | $19.00 Billion | -$7.11 Billion | 0.02x | N/A |
| 2018 | $338.49 Million | $10.84 Billion | -$9.27 Billion | 0.03x | N/A |
| 2019 | $222.68 Million | $17.92 Billion | -$37.26 Billion | 0.01x | N/A |
| 2021 | $249.49 Million | $99.92 Billion | $8.18 Billion | 0.00x | 0.03x |
| 2022 | $163.29 Million | $122.09 Billion | -$5.57 Billion | 0.00x | N/A |
| 2023 | $80.06 Million | $95.55 Billion | -$37.30 Billion | 0.00x | N/A |
| 2024 | $94.58 Million | $129.14 Billion | -$31.55 Billion | 0.00x | N/A |
Competitor Companies of 049180 by Market Capitalization
Companies near Cellumed Co. Ltd in the global market cap rankings as of August 4, 2026.
Key companies related to Cellumed Co. Ltd by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #187 globally with a market cap of $125.14 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #294 globally with a market cap of $88.81 Billion USD ( €75.96 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #343 globally with a market cap of $78.07 Billion USD ( €66.78 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #529 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Intuitive Surgical Inc | NASDAQ:ISRG | $125.14 Billion | $353.33 |
| #294 | EssilorLuxottica S. A. | PA:EL | $88.81 Billion | €164.05 |
| #343 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $78.07 Billion | €80.50 |
| #529 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Cellumed Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Cellumed Co. Ltd's market cap moved from $294.92 Million to $ 37.57 Million, with a yearly change of -18.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩37.57 Million | -12.56% |
| 2025 | ₩42.97 Million | -54.57% |
| 2024 | ₩94.58 Million | +18.14% |
| 2023 | ₩80.06 Million | -50.97% |
| 2022 | ₩163.29 Million | -34.55% |
| 2021 | ₩249.49 Million | +12.04% |
| 2019 | ₩222.68 Million | -34.21% |
| 2018 | ₩338.49 Million | -7.15% |
| 2017 | ₩364.56 Million | -34.95% |
| 2016 | ₩560.42 Million | +90.03% |
| 2015 | ₩294.92 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Cellumed Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.57 Million USD |
| MoneyControl | $37.57 Million USD |
| MarketWatch | $37.57 Million USD |
| marketcap.company | $37.57 Million USD |
| Reuters | $37.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cellumed Co. Ltd
Cellumed Co.,Ltd., a biotechnology company, provides bone graft materials, medical devices, and cosmeceuticals in South Korea. The company offers CLnZyme, a mRNA enzyme; cosmeceuticals, such as FGF7 for skin regeneration and TGFß-1 for tissue regeneration; and electric motorcycles. It provides tissue bank products, such as celluderm powder, ultra, and HD implant for the skin; patellar tendon hemi… Read more